ACVRL1 and vascular malformation: On the one hand this work highlights the complexity of VEGFR2 downstream signalling changes in the absence of ALK1, whilst also opening up the possibility that integrin and/or YAP/TAZ signalling blockers may represent new potential targets to prevent vascular malformations in HHT.